177 related articles for article (PubMed ID: 32389672)
41. Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report.
Al-Zoairy R; Viveiros A; Zoller H; Schneeberger S; Oberhuber G; Gunsilius E; Tilg H; Wolf D; Rudzki JD
J Med Case Rep; 2020 Oct; 14(1):201. PubMed ID: 33099313
[TBL] [Abstract][Full Text] [Related]
42. [Cardiac amyloidosis revealing multiple myeloma].
Denguir H; Ben-Hamda K; Gharbi M; Addad F; Hammami S; Mlika A; Abbes F; Moussa A; Betbout F; Gamra H; Maatouk F; Dridi Z; Zakhama A; Mahjoub S; Ben-Farhat M
Tunis Med; 2005 May; 83(5):300-4. PubMed ID: 16044906
[TBL] [Abstract][Full Text] [Related]
43. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
[TBL] [Abstract][Full Text] [Related]
44. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
[TBL] [Abstract][Full Text] [Related]
45. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
46. Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis.
Aljama MA; Sidiqi MH; Dispenzieri A; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame RM; Kourelis T; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2019 Apr; 3(8):1226-1229. PubMed ID: 30975646
[TBL] [Abstract][Full Text] [Related]
47. Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.
Le Bras F; Molinier-Frenkel V; Guellich A; Dupuis J; Belhadj K; Guendouz S; Ayad K; Colombat M; Benhaiem N; Tissot CM; Hulin A; Jaccard A; Damy T
Eur J Cancer; 2017 May; 76():183-187. PubMed ID: 28334621
[TBL] [Abstract][Full Text] [Related]
48. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
Scott EC; Heitner SB; Dibb W; Meyers G; Smith SD; Abar F; Kovacsovics T; Perez-Avraham G; Stentz A; Frires R; Dibb J; Maziarz RT
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
[TBL] [Abstract][Full Text] [Related]
49. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
50. A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.
Barrett CD; Dobos K; Liedtke M; Tuzovic M; Haddad F; Kobayashi Y; Lafayette R; Fowler MB; Arai S; Schrier S; Witteles RM
JACC Heart Fail; 2019 Nov; 7(11):958-966. PubMed ID: 31606365
[TBL] [Abstract][Full Text] [Related]
51. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
52. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response.
Grogan M; Dispenzieri A; Gertz MA
Heart; 2017 Jul; 103(14):1065-1072. PubMed ID: 28456755
[TBL] [Abstract][Full Text] [Related]
53. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
Minnema MC; Dispenzieri A; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Grogan M; Witteles R; Ruberg FL; Maurer MS; Tran N; Qin X; Vasey SY; Weiss BM; Vermeulen J; Jaccard A
JACC CardioOncol; 2022 Nov; 4(4):474-487. PubMed ID: 36444227
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of autologous stem cell transplant for cardiac AL-amyloidosis and cardiac light chain deposition disease.
Abdallah AA; Alapat D; Kaur V; Atrash S
J Oncol Pharm Pract; 2020 Jul; 26(5):1128-1133. PubMed ID: 31795821
[TBL] [Abstract][Full Text] [Related]
55. Multiple myeloma initially manifesting as a solitary deep ulcer on the tongue: a case study and literature review.
Zhang Y; Wu Y; Yao L; Feng X; Luo X; Chen Q
Eur J Dermatol; 2023 Dec; 33(6):618-623. PubMed ID: 38465542
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.
Nasr SH; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Lacy M; Dispenzieri A; Rajkumar SV; Kyle RA; Leung N
Am J Kidney Dis; 2012 Jun; 59(6):786-94. PubMed ID: 22417785
[TBL] [Abstract][Full Text] [Related]
57. Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis.
Williams MU; Murphy CE; Gore RS; Fentanes E
BMJ Case Rep; 2018 Dec; 11(1):. PubMed ID: 30580294
[TBL] [Abstract][Full Text] [Related]
58. Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein.
Ishiguro K; Hayashi T; Yokoyama Y; Aoki Y; Onodera K; Ikeda H; Ishida T; Nakase H
Intern Med; 2018 Mar; 57(6):783-788. PubMed ID: 29021469
[TBL] [Abstract][Full Text] [Related]
59. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
[TBL] [Abstract][Full Text] [Related]
60. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
Hernández-Reyes J; Galo-Hooker E; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
